08:00 , Mar 3, 2003 |  BC Week In Review  |  Company News

B&C Biopharm, XTL deal

XTL exercised an option under a 2002 deal to acquire development and commercialization rights to a series of preclinical hepatitis C virus (HCV) compounds from B&C. XTL will have exclusive worldwide rights to resulting compounds,...